• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    2/11/22 4:13:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    SC 13G/A 1 d248173dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    NUCANA PLC

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    67022C106

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 67022C106

     

      1.    

      Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)

     

      Hugh S. Griffith

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United Kingdom

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    with

       5.    

      Sole Voting Power

     

      3,902,308 (See Item 4(a) below)

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      3,902,308 (See Item 4(a) below)

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,902,308 (See Item 4(a) below)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      7.1% (See Item 4(b) below)

    12.  

      Type of Reporting Person (See Instructions)

     

      IN


    Item 1.

     

      (a)

    Name of Issuer

    NuCana plc

     

      (b)

    Address of Issuer’s Principal Executive Offices

    3 Lochside Way

    Edinburgh, EH12 9DT

    United Kingdom

    Item 2.

     

      (a)

    Name of Person Filing

    Hugh S. Griffith

     

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o NuCana plc

    3 Lochside Way

    Edinburgh, EH12 9DT

    United Kingdom

     

      (c)

    Citizenship

    Mr. Griffith is a citizen of the United Kingdom

     

      (d)

    Title of Class of Securities

    Ordinary Shares

     

      (e)

    CUSIP Number

    67022C106

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)        ☐     Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)        ☐     Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)        ☐     Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)        ☐     Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)        ☐     An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)        ☐     An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


    (g)        ☐     A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)        ☐     A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)        ☐     A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)        ☐     Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: 3,902,380, which consists of (a) 1,000,000 ordinary shares, (b) 180,121 American Depositary Shares (“ADSs”), each ADS representing one ordinary share, and (c) options to purchase 2,722,259 ordinary shares that are exercisable within 60 days of December 31, 2021. The ordinary shares beneficially owned may be exchanged into ADSs on a one-for-one basis.

     

      (b)

    Percent of class: 7.1% (1)

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: 3,902,380

     

      (ii)

    Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of: 3,902,308

     

      (iv)

    Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    Not applicable.

     

    (1)

    Percentage ownership is calculated based on 52,179,979 ordinary shares outstanding as of December 31, 2021 and assumes that the 2,722,259 ordinary shares underlying the share options that are exercisable within 60 days of December 31, 2021, are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 11, 2022

    Date

    /s/ Hugh S. Griffith

    Hugh S. Griffith
    Get the next $NCNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NuCana downgraded by William Blair

    William Blair downgraded NuCana from Outperform to Mkt Perform

    8/30/24 7:44:58 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana downgraded by Cowen & Co.

    Cowen & Co. downgraded NuCana from Outperform to Market Perform

    3/3/22 6:12:40 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on NuCana with a new price target

    HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

    11/24/21 6:13:12 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

    First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development pr

    8/20/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Announces ADS Ratio Change

    EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces that it will implement the Company's previously disclosed plans to change the ratio of its American Depository Shares ("ADSs") to its ordinary shares from one (1) ADS, representing twenty-five (25) ordinary shares, to one (1) ADS representing five thousand (5,000) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on August 11, 2025 (the "Effective Date").   For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-two hundred reverse ADS split and will have no impact on an ADS holder's pro

    8/1/25 4:05:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

    EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company") announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7, 2025, pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its at-the-market offering. This follows the Company's June 27, 2025 announcement of the agreements to cancel the remaining Series A Warrants, 59.5 million as at June 26, 2025, in exchange for a payment of $3.6 million. This initiative fully eliminates all overhanging rights from the regis

    7/21/25 8:05:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    SEC Filings

    View All

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/20/25 4:20:04 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    8/1/25 4:22:05 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NuCana plc

    6-K - NuCana plc (0001709626) (Filer)

    7/21/25 8:15:16 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NuCana plc

    SC 13G/A - NuCana plc (0001709626) (Subject)

    10/4/24 10:14:46 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NuCana plc (Amendment)

    SC 13D/A - NuCana plc (0001709626) (Subject)

    2/27/24 4:29:36 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NuCana plc (Amendment)

    SC 13G/A - NuCana plc (0001709626) (Subject)

    2/14/24 4:26:01 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCNA
    Leadership Updates

    Live Leadership Updates

    View All

    NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

    EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

    11/1/21 4:01:00 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

    EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

    8/10/21 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care